<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154683</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0945</org_study_id>
    <secondary_id>2019-A01724-53</secondary_id>
    <nct_id>NCT04154683</nct_id>
  </id_info>
  <brief_title>Optical Biopsy in Gynecological Surgery</brief_title>
  <acronym>GYNECOPTIC</acronym>
  <official_title>Diagnostic Performance of Optical Biopsy by Cellvizio® in Gynecological Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optical biopsy is a new technology that generates a real-time, cell-based, high-resolution
      view and analysis of tissues. Observation is instantaneous and non-invasive. This allows
      reliable and fast diagnosis which facilitates decision making as well as patient management.

      The investigator have already conducted a feasibility study on the use of this new technology
      to evaluate ovarian and tubal pre-cancerous lesions in laparoscopy. In this new study, he
      wants to continue investigations, expand its use to other gynecological pathologies, and
      demonstrate the benefit of such a non-invasive technology in gynecology on the one hand in
      the diagnosis of lesions but also to appreciate the margins as accurately as possible
      surgical excision of tumors and / or endometriosis lesions.

      The investigator have set up a prospective monocentric descriptive study. The hypothesis is
      that optical biopsy by Cellvizio® allows to observe in real time microscopically tissues and
      to characterize them in the field of gynecological surgery
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">June 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>correlation optical biopsy and anatomopathology</measure>
    <time_frame>day 0</time_frame>
    <description>The interpretation of the results of the optical biopsy will be compared with the interpretation of the pathological results for each patient.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gynecologic Surgical Procedures</condition>
  <arm_group>
    <arm_group_label>group using Cellvizio® optical biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cellvizio®</intervention_name>
    <description>use of the Cellvizio® optical biopsy</description>
    <arm_group_label>group using Cellvizio® optical biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18 years or more

          -  Informed and signed consent

          -  Planned surgery under laparoscopy and included in the list below:

               -  unilateral or bilateral salpingectomy

               -  hysterectomy

               -  ovariectomy

               -  surgery of endometriosis

               -  surgery for cancer of the cervix, endometrium, ovaries

        Exclusion Criteria:

          -  Interview revealing disorder entailing unacceptable risk of postoperative
             complications: coagulation disorder, immune system disorder, evolutive disease, etc.

          -  Pregnancy or desire of pregnancy during the study period, breastfeeding

          -  Hypersensitivity to Fluorescein or any of its excipients

          -  History of life-threatening reaction during angiography

          -  Known allergic reactions and hypersensitivity

          -  Severe asthma, heart and / or lung disease, diabetes

          -  Person on beta-blocker treatment

          -  Inability to understand information provided

          -  Not covered by a national health insurance scheme, prisoner or under administrative
             supervision
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gautier CHENE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynaecology Department, Hôpital Femme Mère Enfant Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gautier CHENE, MD</last_name>
    <phone>(4) 72 35 58 70</phone>
    <phone_ext>+33</phone_ext>
    <email>gautier.chene@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gynaecology Department, Hôpital Femme Mère Enfant Hospices Civisl de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gautier CHENE, MD</last_name>
      <phone>(4) 72 35 58 70</phone>
      <phone_ext>+33</phone_ext>
      <email>gautier.chene@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gautier CHENE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gery LAMBLIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Chabert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karine Lebail-Carval, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erdogan Nohuz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie, HFME, Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gautier CHENE, MD</last_name>
      <email>gautier.chene@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gautier CHENE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CHABERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géry LAMBLIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karine Lebail-Carval, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erdogan Nohuz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>salpingectomy</keyword>
  <keyword>Cellvizio®</keyword>
  <keyword>optical biopsy</keyword>
  <keyword>unilateral or bilateral salpingectomy</keyword>
  <keyword>ovariectomy</keyword>
  <keyword>Endometriosis</keyword>
  <keyword>surgery for cervical</keyword>
  <keyword>ovarian cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

